Frankfurt - Delayed Quote EUR

Pharvaris N.V. (9EN.F)

18.00 -0.90 (-4.76%)
At close: April 25 at 7:55 PM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
96,913.62
96,913.62
86,714.61
54,138.63
25,006.59
Operating Income
-96,913.62
-96,913.62
-86,714.61
-54,138.63
-25,006.59
Net Non Operating Interest Income Expense
204.02
204.02
-39.25
-282.51
-98.68
Other Income Expense
-3,116.66
-3,116.66
11,100.39
11,760.47
-963.69
Pretax Income
-99,826.26
-99,826.26
-75,653.47
-42,660.66
-26,068.96
Tax Provision
1,048.81
1,048.81
679.09
70.12
-83.25
Net Income Common Stockholders
-100,875.07
-100,875.07
-76,332.56
-42,730.78
-25,985.70
Diluted NI Available to Com Stockholders
-100,875.07
-100,875.07
-76,332.56
-42,730.78
-25,985.70
Basic EPS
-3.03
-2.63
-2.27
-1.40
-0.85
Diluted EPS
-3.03
-2.63
-2.27
-1.40
-0.85
Basic Average Shares
35,796.41
38,391.65
33,585.98
30,411.90
30,519.28
Diluted Average Shares
35,796.41
38,391.65
33,585.98
30,411.90
30,519.28
Total Expenses
96,913.62
96,913.62
86,714.61
54,138.63
25,006.59
Net Income from Continuing & Discontinued Operation
-100,875.07
-100,875.07
-76,332.56
-42,730.78
-25,985.70
Normalized Income
-98,562.50
-98,562.50
-84,569.05
-51,551.13
-25,024.91
Interest Expense
--
--
16.11
267.51
92.47
Net Interest Income
204.02
204.02
-39.25
-282.51
-98.68
EBIT
-96,913.62
-96,913.62
-86,714.61
-54,138.63
-25,976.49
EBITDA
-96,656.07
-96,656.07
-86,561.67
-54,061.26
-25,969.08
Reconciled Depreciation
257.55
257.55
152.94
77.37
7.40
Net Income from Continuing Operation Net Minority Interest
-100,875.07
-100,875.07
-76,332.56
-42,730.78
-25,985.70
Total Unusual Items Excluding Goodwill
-3,116.66
-3,116.66
11,100.39
11,760.47
-963.69
Total Unusual Items
-3,116.66
-3,116.66
11,100.39
11,760.47
-963.69
Normalized EBITDA
-93,539.41
-93,539.41
-97,662.06
-65,821.73
-25,005.40
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-804.10
-804.10
2,863.90
2,940.12
-2.89
12/31/2020 - 2/16/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

4XC1.F KalVista Pharmaceuticals, Inc.
9.30
-8.82%
 
PHARM.AS Pharming Group N.V.
0.8810
-2.60%
 
KALV KalVista Pharmaceuticals, Inc.
10.49
+1.35%
 
ATXS Astria Therapeutics, Inc.
9.17
+1.89%
 
ANNX Annexon, Inc.
4.5900
+3.15%
 
CLNN Clene Inc.
0.3465
+2.82%
 
BCRX BioCryst Pharmaceuticals, Inc.
4.1600
-1.19%
 
BMRN BioMarin Pharmaceutical Inc.
82.17
-9.90%
 
IONS Ionis Pharmaceuticals, Inc.
41.84
-1.44%
 
PTN Palatin Technologies, Inc.
1.7200
-0.58%